Critical role of PTEN for development and progression of nerve sheath tumors in neurofibromatosis type 1

Future Oncology

Volumn 6, Issue 4, 2010, Pages 499-501

  Mawrin, Christian ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

K ras; Malignant peripheral nerve sheath tumor; Neurofibroma; Neurofibromatosis type 1; PTEN

Indexed keywords

FLUORODEOXYGLUCOSE F 18; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RAPAMYCIN;

ALLELE; CANCER MORTALITY; CELL PROLIFERATION; DISEASE COURSE; EARLY DIAGNOSIS; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MORBIDITY; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; NONHUMAN; NOTE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 77950607617     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.29     Document Type: Note

References (9)

1. Gregorian C, Nakashima J, Dry SM et al.: PTEN dosage is essential for neurofibroma development and malignant transformation. Proc. Natl Acad. Sci. USA 106(46), 19479-19484 (2009).
2. Kourea HP, Cordon-Cardo C, Dudas M, Leung D, Woodruff JM: Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am. J. Pathol. 155(6), 1885-1891 (1999).
3. Menon AG, Anderson KM, Riccardi VM et al.: Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc. Natl Acad. Sci. USA 87(14), 5435-5439 (1990).
4. Mawrin C, Kirches E, Boltze C, Dietzmann K, Roessner A, Schneider-Stock R: Immunohistochemical and molecular analysis of p53, Rb, and PTEN in malignant peripheral nerve sheath tumors. Virchows Arch. 440(6), 610-615 (2002). (Pubitemid 34809693)
5. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K: The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl Acad. Sci. USA 102(24), 8573-8578 (2005). (Pubitemid 40862777)
6. Holtkamp N, Okuducu AF, Mucha J et al.: Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis 27(3), 664-671 (2006). (Pubitemid 43372895)
7. Bhola P, Banerjee S, Mukherjee J et al.: Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. Int. J. Cancer 126(2), 563-571 (2010).
8. Li H, Velasco-Miguel S, Vass WC, Parada LF, DeClue JE: Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res. 62(15), 4507-4513 (2002). (Pubitemid 34827315)
9. Holtkamp N, Atallah I, Okuducu AF et al.: MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia 9(8), 671-677 (2007). (Pubitemid 47328086)